Vote Scores

Home / Companies / Neuphoria Therapeutics Inc. / 12 Dec 2025

Meeting · year to 30 June 202625 filers reporting

Neuphoria Therapeutics Inc.: meeting of 12 Dec 2025

Votes reported on Form N-PX, item by item

25 Form N-PX filers reported votes at the Neuphoria Therapeutics Inc. meeting of 12 Dec 2025. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

4 nominees; 83.3% of reported votes for; no filer withheld from or voted against at least one nominee.

20 vote records from 4 filers. 0 of the 4 filers that marked the item either way voted against management.

75.0% for0.0% against25.0% other0.0% against management4 filers
2

DIRECTOR ELECTIONSSecurity holder

Director elections (nominees put forward by security holders)

4 nominees; 0.0% of reported votes for; 4 filers withheld from or voted against at least one nominee.

20 vote records from 4 filers. 0 of the 4 filers that marked the item either way voted against management.

0.0% for0.0% against100.0% other0.0% against management4 filers
3

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

45 vote records from 25 filers. 2 of the 16 filers that marked the item either way voted against management. 9 filers reported this item without a management mark.

52.0% for4.0% against44.0% other12.5% against management25 filers34.5% for23.4% against42.1% other40.4% against management368,623 reported shares
4

SECTION 14A SAY-ON-PAY VOTESIssuer

Frequency of the say-on-pay vote

one year: 15 filers; not applicable: 2 filers; three years: 1 filer; do not vote: 1 filer.

46 vote records from 25 filers. 15 of the 17 filers that marked the item either way voted against management. 8 filers reported this item without a management mark.

0.0% for0.0% against100.0% other88.2% against management25 filers0.1% for0.0% against99.9% other92.2% against management203,165 reported shares
5

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

10 vote records from 4 filers. 0 of the 4 filers that marked the item either way voted against management.

75.0% for0.0% against25.0% other0.0% against management4 filers55.5% for0.0% against44.5% other0.0% against management159,626 reported shares

How the largest families voted

Family1. Directors2. Directors3. Say-on-pay4. Pay-vote frequency5. Auditor
VanguardForAbstain or withholdForSplit or no vote *For
FidelityForAbstain or withholdForSplit or no vote *For
State Street and SPDRNo reportNo reportForSplit or no vote *No report
Goldman SachsNo reportNo reportSplit or no voteSplit or no voteNo report
Northern Trust and FlexSharesNo reportNo reportSplit or no voteSplit or no voteNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Neuphoria Therapeutics Inc. meeting?

25 Form N-PX filers reported votes at the meeting of 12 Dec 2025. On say-on-pay, 2 of 16 voted against management (12.5%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Neuphoria Therapeutics Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Neuphoria Therapeutics Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Neuphoria Therapeutics Inc. with a meeting date within three days of 12 Dec 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.